Angiostatin

Drug Profile

Angiostatin

Latest Information Update: 16 Nov 2010

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Alchemgen Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 16 Nov 2010 Discontinued - Preclinical for Solid tumours in Asia (SC)
  • 17 Oct 2007 Preclinical trials in Solid tumours in Asia (SC)
  • 07 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top